Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Using Copeptin to Predict Response to Tolvaptan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients with a history of chronic symptomatic heart failure, defined as dyspnea on exertion or edema, due to cardiac dysfunction, of at least one month's duration~2. Left ventricular ejection fraction ≤ 45% as documented by quantitative assessment by an accepted imaging technique within one year of screening~3. Meet baseline copeptin criteria for entry~4. Currently taking a diuretic (with diuretic defined as any loop or thiazide diuretic or aldosterone antagonist at any dose)~Exclusion Criteria:~1. Current New York Heart Association Functional Class IV heart failure~2. Patients who are felt to be volume depleted based on clinical examination or need to reduce diuretic administration~3. Presence of clinical contraindications to tolvaptan~4. Episode of acute myocardial infarction or acute coronary syndrome within the past 3 months~5. Cardiovascular surgical procedure within the past 4 weeks~6. CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid cardiomyopathy.~7. History of primary significant liver disease or acute hepatic failure, as defined by the investigator.~8. Chronic uncontrolled diabetes mellitus as determined by the investigator.~9. Supine systolic arterial blood pressure \< 90 mmHg at screening~10. Serum creatinine \> 3.5 mg/dL at screening~11. Serum potassium \> 5.5 mEq/L or \< 3.5 mEq/L at screening~12. Subjects currently treated with hemofiltration or dialysis~j. Subjects judged by the investigator to be unable to maintain accurate intake and output during their hospitalization related to medical or other problems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: OTHER): Single arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).